Cargando…

The Clinical Effectiveness and Safety of Vaccinations against COVID-19 in HIV-Positive Patients: Data from Observational Study in Poland

People living with HIV (PLWH) are a heterogeneous group of immunocompromised persons, yet underrepresented in randomized clinical trials leading to vaccination registration. Detectable HIV viral load and having chronic comorbidities may increase the risk of severe COVID-19 outcomes in this group of...

Descripción completa

Detalles Bibliográficos
Autores principales: Bieńkowski, Carlo, Skrzat-Klapaczyńska, Agata, Firląg-Burkacka, Ewa, Horban, Andrzej, Kowalska, Justyna D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056207/
https://www.ncbi.nlm.nih.gov/pubmed/36992098
http://dx.doi.org/10.3390/vaccines11030514
_version_ 1785016068801036288
author Bieńkowski, Carlo
Skrzat-Klapaczyńska, Agata
Firląg-Burkacka, Ewa
Horban, Andrzej
Kowalska, Justyna D.
author_facet Bieńkowski, Carlo
Skrzat-Klapaczyńska, Agata
Firląg-Burkacka, Ewa
Horban, Andrzej
Kowalska, Justyna D.
author_sort Bieńkowski, Carlo
collection PubMed
description People living with HIV (PLWH) are a heterogeneous group of immunocompromised persons, yet underrepresented in randomized clinical trials leading to vaccination registration. Detectable HIV viral load and having chronic comorbidities may increase the risk of severe COVID-19 outcomes in this group of patients. We aimed to assess the efficacy and safety of vaccinations against COVID-19 in PLWH. Materials and Methods: We performed a retrospective analysis of medical records of HIV-positive individuals routinely followed up between 1 January 2021 and 30 April 2022 that were at the HIV Outpatient Clinic in Warsaw. The analysis included data on the type and date of administration of subsequent doses of COVID-19 vaccination, adverse vaccine reactions, and the history of SARS-CoV-2 infection. Results: In total, 217 patients were included in the analysis, with a median age of 43 years (IQR: 35.5–51.5 years) and median CD4+ count of 591 cells/uL (IQR: 459.5–745.0 cells/uL). Most of the patients were male (191/217, 88.0%) and were vaccinated with the BNT162b2 vaccine (143/217, 65.9%). None of the patients diagnosed with COVID-19 required hospitalization. Vaccine adverse events (VAE) mostly occurred after the 1st dose (in 33/217 (15.2%)), and none of them were severe or required medical care. Conclusions: In our cohort of patients, vaccination against COVID-19 proved to be safe and effective against a severe course of the disease among people living with HIV. However, vaccination, to a lesser degree, protects against mild SARS-CoV-2 infection. Longer observations are required in order to assess the sustainability of protection against severe COVID-19 in this group of patients.
format Online
Article
Text
id pubmed-10056207
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100562072023-03-30 The Clinical Effectiveness and Safety of Vaccinations against COVID-19 in HIV-Positive Patients: Data from Observational Study in Poland Bieńkowski, Carlo Skrzat-Klapaczyńska, Agata Firląg-Burkacka, Ewa Horban, Andrzej Kowalska, Justyna D. Vaccines (Basel) Brief Report People living with HIV (PLWH) are a heterogeneous group of immunocompromised persons, yet underrepresented in randomized clinical trials leading to vaccination registration. Detectable HIV viral load and having chronic comorbidities may increase the risk of severe COVID-19 outcomes in this group of patients. We aimed to assess the efficacy and safety of vaccinations against COVID-19 in PLWH. Materials and Methods: We performed a retrospective analysis of medical records of HIV-positive individuals routinely followed up between 1 January 2021 and 30 April 2022 that were at the HIV Outpatient Clinic in Warsaw. The analysis included data on the type and date of administration of subsequent doses of COVID-19 vaccination, adverse vaccine reactions, and the history of SARS-CoV-2 infection. Results: In total, 217 patients were included in the analysis, with a median age of 43 years (IQR: 35.5–51.5 years) and median CD4+ count of 591 cells/uL (IQR: 459.5–745.0 cells/uL). Most of the patients were male (191/217, 88.0%) and were vaccinated with the BNT162b2 vaccine (143/217, 65.9%). None of the patients diagnosed with COVID-19 required hospitalization. Vaccine adverse events (VAE) mostly occurred after the 1st dose (in 33/217 (15.2%)), and none of them were severe or required medical care. Conclusions: In our cohort of patients, vaccination against COVID-19 proved to be safe and effective against a severe course of the disease among people living with HIV. However, vaccination, to a lesser degree, protects against mild SARS-CoV-2 infection. Longer observations are required in order to assess the sustainability of protection against severe COVID-19 in this group of patients. MDPI 2023-02-22 /pmc/articles/PMC10056207/ /pubmed/36992098 http://dx.doi.org/10.3390/vaccines11030514 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Bieńkowski, Carlo
Skrzat-Klapaczyńska, Agata
Firląg-Burkacka, Ewa
Horban, Andrzej
Kowalska, Justyna D.
The Clinical Effectiveness and Safety of Vaccinations against COVID-19 in HIV-Positive Patients: Data from Observational Study in Poland
title The Clinical Effectiveness and Safety of Vaccinations against COVID-19 in HIV-Positive Patients: Data from Observational Study in Poland
title_full The Clinical Effectiveness and Safety of Vaccinations against COVID-19 in HIV-Positive Patients: Data from Observational Study in Poland
title_fullStr The Clinical Effectiveness and Safety of Vaccinations against COVID-19 in HIV-Positive Patients: Data from Observational Study in Poland
title_full_unstemmed The Clinical Effectiveness and Safety of Vaccinations against COVID-19 in HIV-Positive Patients: Data from Observational Study in Poland
title_short The Clinical Effectiveness and Safety of Vaccinations against COVID-19 in HIV-Positive Patients: Data from Observational Study in Poland
title_sort clinical effectiveness and safety of vaccinations against covid-19 in hiv-positive patients: data from observational study in poland
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056207/
https://www.ncbi.nlm.nih.gov/pubmed/36992098
http://dx.doi.org/10.3390/vaccines11030514
work_keys_str_mv AT bienkowskicarlo theclinicaleffectivenessandsafetyofvaccinationsagainstcovid19inhivpositivepatientsdatafromobservationalstudyinpoland
AT skrzatklapaczynskaagata theclinicaleffectivenessandsafetyofvaccinationsagainstcovid19inhivpositivepatientsdatafromobservationalstudyinpoland
AT firlagburkackaewa theclinicaleffectivenessandsafetyofvaccinationsagainstcovid19inhivpositivepatientsdatafromobservationalstudyinpoland
AT horbanandrzej theclinicaleffectivenessandsafetyofvaccinationsagainstcovid19inhivpositivepatientsdatafromobservationalstudyinpoland
AT kowalskajustynad theclinicaleffectivenessandsafetyofvaccinationsagainstcovid19inhivpositivepatientsdatafromobservationalstudyinpoland
AT bienkowskicarlo clinicaleffectivenessandsafetyofvaccinationsagainstcovid19inhivpositivepatientsdatafromobservationalstudyinpoland
AT skrzatklapaczynskaagata clinicaleffectivenessandsafetyofvaccinationsagainstcovid19inhivpositivepatientsdatafromobservationalstudyinpoland
AT firlagburkackaewa clinicaleffectivenessandsafetyofvaccinationsagainstcovid19inhivpositivepatientsdatafromobservationalstudyinpoland
AT horbanandrzej clinicaleffectivenessandsafetyofvaccinationsagainstcovid19inhivpositivepatientsdatafromobservationalstudyinpoland
AT kowalskajustynad clinicaleffectivenessandsafetyofvaccinationsagainstcovid19inhivpositivepatientsdatafromobservationalstudyinpoland